Specialty Pharmacy

Investigators examined the impact of daily oral tenofovir disoproxil fumarate in combination with emtricitabine to see the effect on the microbiota in South African women.

Sonidegib binds to and inhibits a transmembrane protein to disrupt hedgehog pathway signal transduction and leading to antitumor activity in patients with locally advanced basal cell carcinoma.

Deutetrabenazine is the only VMAT2 inhibitor approved by the FDA for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntington disease.

Rachel K. Anderson, PharmD, CSP, clinical program manager at Alliance Rx Walgreens Pharmacy, discusses the impact pharmacists have on the care journey for patients with multiple myeloma.

Immune function has been found to play a significant role in multiple myeloma.

By targeting the viral conical core, these ARTs could disrupt the process of assembly and/or disassembly of the virus and result in its suppression.

Specialty pharmacy reports case of alirocumab prescription with mg incorrectly typed instead of mL.

Pharmaceutical companies are looking into AI as the new method to not only reduce research and development costs, but also prevent costly errors.

Further, the survey showed that fewer than half of women would flag redness of the breast, thickening of the skin, or 1 breast feeling warmer and heavier than the other as possible symptoms.

A presentation at the AMCP Nexus conference focuses on the health care disparities and pharmacotherapy options for gender affirmation.

Presentation at the AMCP Nexus conference focuses on midterm election outlook and a plug for the Pre-approval Information Exchange Act.

This World Standards Week, Carrie Harney, JD, vice president, US Government and Regulatory Affairs at US Pharmacopeia (USP), explains how pharmacists contribute to USP’s standards setting process.

The study will evaluate the safety, tolerability, and efficacy of the in combination in patients both with and without prior exposure to a KRASG12C inhibitor.

Keynote speaker at the AMCP Nexus conference discusses recent FDA approvals and those scheduled over the next year.

Jeremy Graff, chief scientific officer at IMV, discusses why the development of viable cancer vaccines is a bit more slow-going in comparison to the fast-paced development of COVID-19 vaccines during the pandemic.

Zanubrutinib (Brukinsa) is a small molecule Bruton’s tyrosine kinase inhibitor under evaluation as a monotherapy and in combination with other treatments for various B-cell malignancies.

Women who make a difference in the industry honored on #WomenPharmacistDay.

The specialty pharmacy space can tie into public health populations through many different initiatives.

Heidi D. Finnes, PharmD, BCOP, FHOPA, president of HOPA discusses some key recommendations to women interested in pursuing leadership roles in oncology pharmacy.

Omidubicel is a stem cell-based product that utilizes nicotinamide to inhibit differentiation and to increase the migration, bone marrow homing, and engraftment efficiency of hematopoietic progenitor cells.

Nakia Eldridge, PharmD, MBA, discussed her career, the impacts of COVID-19 on women in pharmacy, and how mentorship can pave the way for more women pharmacists.

As part of American Pharmacist Month, Pharmacy Times is asking experts what they believe the value of the pharmacist is.

This year marks the fifth annual Women Pharmacist Day after it was founded in 2018.

Selpercatinib is an oral selective RET kinase inhibitor approved for the treatment of metastatic RET fusion-positive non-small cell lung cancer and for metastatic thyroid cancer.

In a trial, sacituzumab govitecan-hziy demonstrated a 34% reduction in the risk of disease progression or death compared with physician’s choice chemotherapy.

Suzanne Soliman, PharmD, BCMAS, discusses how she will be celebrating the important contributions of women pharmacists.

As part of American Pharmacist Month, Pharmacy Times is asking experts what they believe the value of the pharmacist is.

Rucaparib is the only PARP inhibitor demonstrated to have better outcomes than a docetaxel-containing control arm, according to researchers.